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Abstract 
Background: The mechanisms underlying the therapeutic activity of interferon-β in multiple sclerosis are still not 
completely understood. In the present study, we evaluated the short and long-term effects of interferon-β treatment 
on different subsets of regulatory T cells in relapsing–remitting multiple sclerosis patients biologically responsive to 
treatment because of mixovirus resistance protein A inducibility.
Methods: In this prospective longitudinal study, subsets of natural regulatory T cells (naïve, central memory and 
effector memory) and inducible regulatory T cells (Tr1), as well as in vitro-induced regulatory T cells (Tr1-like cells), 
were simultaneously quantified by flow cytometry in samples prepared from 148 therapy-naïve multiple sclerosis 
patients obtained before and after 6, 12, 18, and 24 months of interferon-β-1a treatment. mRNA for interleukin-10 and 
Tr1-related genes (CD18, CD49b, and CD46, together with Cyt-1 and Cyt-2 CD46-associated isoforms) were quantified 
in Tr1-like cells.
Results: Despite profound inter-individual variations in the modulation of all regulatory T-cell subsets, the per-
centage of natural regulatory T cells increased after 6, 12, and 24 months of interferon-β treatment. This increase 
was characterized by the expansion of central and effector memory regulatory T-cell subsets. The percentage of 
Tr1 significantly enhanced at 12 months of therapy and continued to be high at the subsequent evaluation points. 
Patients experiencing relapses displayed a higher percentage of naïve regulatory T cells and a lower percentage of 
central memory regulatory T cells and of Tr1 before starting interferon-β therapy. In addition, an increase over time of 
central memory and of Tr1 was observed only in patients with stable disease. However, in vitro-induced Tr1-like cells, 
prepared from patients treated for 24 months, produced less amount of interleukin-10 mRNA compared with pre-
treatment Tr1-like cells.
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Background
Multiple sclerosis (MS) is an autoimmune, inflamma-
tory and chronic disease of central nervous system. 
Interferon-β (IFN-β) is one of the main treatments of 
the relapsing–remitting form of MS (RRMS); however, 
its mechanism of action is multifactorial and still under 
debate. A better understanding of the actions underlying 
the effects of IFN-β and its anti-inflammatory properties 
would help to clarify why IFN-β is not effective in all MS 
patients and to identify subjects that may benefit most 
from IFN-β treatment and those that should be directed 
to a therapy switch.
Given the central role in suppressing T-cell activity 
and inflammation, regulatory T cells (Treg) are poten-
tial biomarkers of IFN-β therapeutic efficacy in MS 
[1]. Treg can be divided into naturally occurring Treg 
(nTreg) and inducible Treg (iTreg) [2]. FoxP3 is the clas-
sic marker of Treg and the presence of the FoxP3 exon2 
isoform has proved to pinpoint the  CD4+ Treg with the 
highest regulatory activity [2, 3]. Treg can also be identi-
fied as  CD4+CD25+ cells with low expression or absence 
of interleukin-7 receptor alpha chain (IL‐7R or CD127) 
[4]. Antigen-specific activation in secondary lymphoid 
organs gives rise to effector memory Treg (TregEM) that 
migrate to antigen-expressing peripheral tissues, where 
they stably reside or recirculate between blood and non-
lymphoid tissues, and central memory Treg (TregCM) 
that remain in secondary lymphoid organs [5]. The 
chemokine receptor CCR7, which regulates cellular traf-
ficking both in lymphoid and inflamed sites, is the marker 
that distinguishes TregCM and TregEM and is responsi-
ble for the ex vivo function of nTreg [5]. The expression 
of CD120b (also known as tumour necrosis factor recep-
tor 2 or TNFR2) on the cell surface appears to confer to 
nTreg a maximal suppressive activity [6].
The identification of Tr1, one of the main iTreg subsets, 
is complex although some reports propose the combined 
expression of CD18 and CD49b integrins as Tr1 cell-spe-
cific markers [7]. Furthermore, it is possible to generate 
in  vitro-induced Tr1 (Tr1-like cells) by stimulating cells 
with anti-CD3 and anti-CD46 monoclonal antibodies 
(MoAbs). The anti-CD3 MoAb is used as a general T-cell 
activation stimulus, while anti-CD46 MoAb is a specific 
Tr1-like cell inducer [8].
Several researchers have studied the effects of IFN-β 
treatment either on peripheral nTreg or iTreg [9–15], 
but no previous study has investigated the modulation 
of nTreg and their subsets, Tr1 and Tr1-like cells in the 
same cohort of patients. Most reports on Treg are based 
on cross-sectional studies and limited by selection bias, 
such as a small number of included patients and a short 
follow-up. Finally, most studies missed the detection of 
anti-IFN-β antibodies affecting the IFN-β bioactivity [16].
Therefore, we performed a long-term study to quantify 
nTreg and their subsets, Tr1 and Tr1-like cells in a large 
cohort of therapy-naïve MS patients who initiated IFN-β 
treatment and were biologically IFN-β responders.
Methods
Patients and controls
This prospective longitudinal study enrolled therapy-
naïve patients (n = 148) involving 23 MS centres across 
Italy. Samples from age-matched healthy subjects served 
as controls (Ctrl) for in vitro studies.
All subjects signed an informed consent form. The 
study was approved by Ethical Committees of Brescia 
(protocol n. 28961 of June 21, 2012) and of each MS 
Center, and was performed in accordance with the spe-
cific Italian regulation on observational studies and in 
compliance with the Italian regulations on non-interven-
tional trials.
The 148 patients were included if they received a con-
firmed diagnosis of RRMS, according to the 2010 Mc 
Donald criteria [17]. They were treated with 22 or 44 μg 
of IFN-β-1a subcutaneous, injected three times per week. 
Each patient was followed for a 24-months period start-
ing from the first IFN-β administration, except in cases 
of dropout from the study, who had a shorter follow-
up. Blood samples were obtained before the first IFN-β 
injection (T0) and then at 6 (T6), 12 (T12), 18 (T18), 
and 24 (T24) months of follow-up. Blood samples at T12 
and T24 were also collected in PAXgene tubes (Blood 
RNA Tube, PreAnalytiX, Hombrechtikon, Switzerland) 
11–13 h after the last IFN-β administration, in order to 
allow for a correct mixovirus resistance protein A (MxA) 
mRNA induction assessment.
Results were reported according with the STROBE 
guidelines [18].
Magnetic resonance imaging examination
Magnetic resonance imaging (MRI) have been performed 
using a 1.5 T scanner commonly used in clinical routine. 
Conclusion: Interferon-β induces the expansion of T regulatory subsets endowed with a high suppressive activity, 
especially in clinically stable patients. The overall concurrent modulation of natural and inducible regulatory T-cell 
subsets might explain the therapeutic effects of interferon-β in multiple sclerosis patients.
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T1-weighted images with administration of a single dose 
of contrast medium (gadolinium-DTPA, 0.1  mmol/kg; 
i.e. 0.2  ml/kg) as well as T2-weighted images (double-
echo MRI brain scans) have been performed according 
to Italian clinical practice (https ://www.ncbi.nlm.nih.gov/
pubme d/23828 372). Number and volume of gadolinium-
enhancing lesions on T1-weighted and new/enlarging 
lesions on T2-weighted sequences have been centrally 
measured by MRI experienced readers at the centralized 
MRI Lab (Fondazione Don Gnocchi Institute, Milan).
Sample processing
Twenty ml of blood collected in ethylenediaminetet-
raacetic acid tubes were received by a controlled-temper-
ature next-day shipping at every time point. An aliquot of 
blood underwent flow cytometry immediately, while the 
remaining blood underwent standard Ficoll density gra-
dient centrifugation in order to obtain peripheral blood 
mononuclear cells (PBMC), which were then stored in 
liquid nitrogen in a solution containing 90% fetal calf 
serum (FCS) and 10% dimethylsulfoxide until the in vitro 
experiments. Blood for MxA mRNA quantification was 
stored at − 20 °C for up to 6 months.
Treg subset phenotyping
T-cell subsets were assessed by 8-colour flow cytometry 
analysis on 150  μl whole blood. Cells were stained with 
various combinations of optimal staining concentrations 
(previously determined by titrations) of horizon V500 
anti-CD4, APC-H7 anti-CD45RA, BV421 anti-CD25, 
PerCP-Cy5-5 anti-CCR7, PE-Cy7 anti-CD127, anti-PE 
CD120b, FITC anti-CD49b, and APC anti-CD18 MoAbs 
(BD Pharmingen, S. Diego, CA; Biolegend, S. Diego, CA 
and eBioscience, Vienna, Austria).
The nTreg population was identified as 
 CD4+CD25+CD127low/‒ cells. By using the anti-
CD45RA and anti-CCR7 antibodies, the fol-
lowing nTreg subsets were identified: naïve 
Treg  CD4+CD25+CD127low/‒CD45RA+CCR7+, 
TregCM  CD4+CD25+CD127low/‒CD45RA‒CCR7+, and 
TregEM  CD4+CD25+CD127low/‒CD45RA‒CCR7‒ [19]. 
 CD4+CD25+CD127low/‒ cells were also characterized 
for the expression of CD120b marker. The values of all 
these subsets were expressed as percentage and absolute 
number.
Similarly,  CD4+ cells were evaluated for CD18 
and CD49b markers to define the Tr1 population as 
 CD4+CD18+CD49b+ lymphocytes [7]. This cell subset 
was also evaluated before and after in vitro induction of 
Tr1-like cells, starting from  CD4+ cells, isolated from 
PBMC of patients and Ctrl, stimulated with anti-CD3 and 
anti-CD46 MoAbs in presence of interleukin-2 (IL-2).
Data acquisition was performed with a 3-laser 8-color 
FACSCanto II cytometer and analyzed with the FACS-
Diva software (BD Biosciences, San Jose, CA) and FlowJo 
(FlowJo LLC, Ashland, OR), and results were expressed 
as percentage of cells or as mean fluorescence intensity 
(MFI).
Induction of Tr1‑like cells
In vitro induction of Tr1-like cells was performed after 
thawing about 20 × 106 PBMC of 60 patients obtained 
before IFN-β therapy initiation and after 12 and 
24 months. Patients were randomly chosen among those 
who completed the T24 follow-up and resulted always 
MxA-induced.  CD4+ cells (purity > 95% according to flow 
cytometer analysis) were prepared using the  CD4+ T 
Cell Isolation Kit (Miltenyi Biotec, Gladbach, Germany), 
according to manufacturer’s protocol. 3 × 106  CD4+ cells, 
diluted in complete RPMI 1640 (2 mM l-glutamine, 100 
U/ml penicillin, and 100  µg/ml streptomycin) supple-
mented with 20% FCS and 40 U/ml of human recom-
binant IL-2 (Sigma-Aldrich, Saint Louis, MO), were 
incubated in previously coated 24 well-plates with 10 μg/
ml of anti-CD3 (clone OKT3; BioXcell, West Lebanon, 
NH) and anti-CD46 (clone E4.3; Santa Cruz Biotech-
nology, Santa Cruz, CA) MoAbs; the MoAbs used for 
coating were not eliminated, therefore their final concen-
tration was 5 µg/ml. Remaining 3 × 106  CD4+ cells were 
diluted in complete RPMI 1640 supplemented with 20% 
FCS, without any type of stimulus.
Total RNA for molecular studies was extracted from 
2 × 106 of both unstimulated and stimulated  CD4+ cells 
for 24 h; 1 × 106  CD4+ cells were left in culture for further 
24 h for Tr1-like cell quantification by flow cytometry.
Real‑time PCR for quantification of MxA and Tr1‑related 
gene mRNAs
Total RNA was prepared either from whole blood col-
lected into PAXgene tubes using the PAXgene Blood 
RNA Kit (PreAnalytiX), or extracted from unstimulated 
and anti-CD3/CD46 MoAb co-stimulated  CD4+ cells 
using NucleoSpin RNA II kit (Machery-Nagel, Düren, 
Germany). RNA to cDNA retrotranscription was per-
formed with Taqman reverse transcription reagents 
using random hexamers. cDNA for MxA mRNA quan-
tification was subjected to quantitative real-time PCR 
in a 7500 Fast Real-time PCR system, using primers and 
probes specific for MxA and the glyceraldehyde 3-phos-
phate-dehydrogenase as reference gene, as reported [20].
Taqman gene expression assay (Thermo Fisher Scien-
tific, Waltham, MA) were used to analyze the expression 
of mRNA for the following genes: interleukin-10 (IL-10; 
Hs00961622_m1, VIC), CD46 (Hs00611256_m1, FAM), 
CD49b (Hs00158127_m1, VIC), CD18 (Hs00164957_m1, 
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FAM): glucuronidase β gene (GUSB-Hs00939627_m1, 
FAM) was chosen as the housekeeping reference gene.
The primers and probes for Cyt-1 and Cyt-2 CD46 iso-
form quantification were the following:
Cyt-1: 5′-GAT GAG ACC CAC AGA GAA GTA AAA 
TTTAC-3′ (forward), 5′-ACC ATC TGC TTT CCT TTT 
AAT GAT AAA-3′ (reverse), and 5′-FAM-TCT CTC TGA 
GAA GGA GAG ATG AGA GAA AGG TTTGC-TAMRA-3′ 
(probe).
Cyt-2: 5′-AGA AGA AAG GGA AAG CAG ATGGT-3′ 
(forward), 5′-CAG AGC AGA GAG GCT GAA TAG ATT 
C-3’ (reverse) and 5′-HEX-GAG CTG AAT ATG CCA CTT 
ACC AGA CTA AAT CAA CCA C-TAMRA-3′ (probe).
The Cyt-1 primers were designed in the Cyt-1-specific 
exon 13, while the Cyt-2 forward primer overlap the 
junction between exons 12 and 14. Assays were run on a 
7500 Fast Real-time PCR instrument (Life Technologies, 
Foster City, CA) and data were analyzed with the 7500 
Fast System SDS software (Life Technologies) to deter-
mine the cycle threshold (Ct). Results were then obtained 
using a modified version of the comparative “ΔΔ Ct” 
method and expressed as normalization ratio (NR) that 
took into account the different amplification efficiencies 
of the primer set used for the different targets, as sug-
gested by Pfaffl et al. [21].
Statistical analysis
For the analysis of follow-up data (ex vivo flow cytometry 
studies), in order to control for any selection bias due to 
study dropout of patients non responsive to the therapy 
(or for any non-random loss of participants), an intention 
to treat analysis was performed using all available samples 
(i.e. if a subject dropped out from the study, any available 
samples of previous time points were retained). There-
fore, ANOVA for repeated measures using linear mixed 
models (with fixed and random effects) were employed, 
as these methods allow analysis even in case of missing 
samples. Planned contrasts or Bonferroni-corrected post 
hoc tests were performed to compare subgroups. Corre-
lations were analyzed using the Pearson correlation coef-
ficient. Data of in vitro gene expression studies that did 
not fulfill normality assumptions were log-converted; if 
outliers were detected, data were excluded from the anal-
ysis. Multivariable regression was fit using linear mixed 
models, with stepwise backward elimination of covari-
ates. To provide a description of the samples, categorical 
variables (for instance, gender and enhancing lesion yes/
no) are expressed as count (percentage) and continuous 
variables as mean and standard deviation (SD). Between-
group differences were tested using the Chi squared or 
the two independent sample t- tests for categorical and 
continuous variables, respectively. For statistical analysis 
on new relapses and new lesions, after a mixed ANOVA, 
the Newman-Keuls post hoc test was used.
P-value threshold for significance was set at 0.05. If not 
otherwise reported, significant p-values in the figures are 
< 0.05. Data were analyzed using Stata Statistical Soft-
ware Release 12 (StataCorp LP, College Station, TX) and 
GraphPad Prism 5.0 (GraphPad Software, San Diego, Ca).
Results
Patients
The number of patients enrolled in the study and drop-
outs occurring at each time point are shown in Addi-
tional file  1: Table  S1. Reasons for dropouts included: 
adverse events, non-compliance, disease worsening, 
therapy switch, consent withdrawal, investigator deci-
sion, and loss to follow-up. At the end of the study, the 
dropout rate was 42%.
The potential bias determined by the presence of anti-
IFN-β neutralizing antibodies, which would impair 
the IFN-β signaling cascade and biological effects, was 
bypassed including only biologically responsive to IFN-β 
patients, having MxA values (NR) higher than the pre-
viously determined cut-off (NR < 3.78) [20] at 12 and 
24 months of treatment (Additional file 2: Table S2).
Flow cytometry analysis of nTreg and Tr1 in IFN‑β‑treated 
patients
Analysis of nTreg subsets and Tr1 was performed by using 
a multiparameter flow cytometry assay, according to the 
gating strategy presented in the Additional file 3: Figure 
S1. For each sample a total number of 25,000 events, 
gated on  CD4+ cells, was acquired. This value ensures the 
compliance with the criteria for limit of detection (LOD) 
and lower limit of quantification (LLOQ) acceptance for 
rare cell populations. Furthermore, a minimum of 50 
events, which are widely accepted as a standard threshold 
for reproducible enumeration of a cell population, was 
always measured for each of the nTreg subsets [22].
The percentage of nTreg significantly increased during 
the study period (Fig.  1a) compared with the percent-
age of nTreg at pre-therapy time point (T0); in particular, 
these cells significantly raised between T0 and T6, T6 and 
T12, and T18, and T24. The modification of nTreg per-
centage was characterized by the reduction of naïve Treg 
(Fig. 1b) and by the expansion of both TregCM (Fig. 1c) 
and TregEM (Fig. 1d) subsets. Indeed, the percentage of 
TregCM was higher than at pre-treatment period at all 
time points, but this increase was more evident between 
T6 and T12. TregEM augmented only at T24, when the 
number of TregEM was significantly higher in com-
parison to previous time points and to pre-therapy. The 
percentage of  CD120b+ nTreg increased slightly, yet sig-
nificantly, at T24 in comparison to pre-therapy values 
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(Fig.  1e). The percentage of Tr1 significantly enhanced 
at T12 and continued to be high at the subsequent time 
points (Fig. 1f ). In addition, despite the significant, pro-
found decrease of the number of lymphocytes (Addi-
tional file  4: Figure S2A), the absolute number of this 
Treg subset increased during the therapy (Additional 
file 4: Figure S2F).
Tr1‑like cells after in vitro stimulation with anti‑CD3/CD46 
MoAbs
The percentage of Tr1-like cells (defined by the 
 CD4+CD18+CD49b+ phenotype) significantly increased 
after in  vitro stimulation with anti-CD3 and anti-CD46 
MoAbs (ANOVA main effect p < 0.001; interaction not 
significant) in both patients and Ctrl. In addition, in 
patients, IFN-β induced a slightly significant increase 
in Tr1-like cells at T24 compared to pre-therapy period 
(Fig.  2a). After stimulation, the expression of the CD18 
surface marker, determined by flow cytometry as MFI, 
only increased (ANOVA main effect p < 0.001; interac-
tion not significant) in patients (for Ctrl, p = 0.07, not sig-
nificant), but was not affected by IFN-β therapy, because 
it remained unchanged over time in treated patients 
(Fig. 2b). Conversely, the expression of CD49b seems to 
be affected by the long term therapy because not only 
its MFI increased after stimulation, but it also raised 
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independently of the in  vitro stimulation (i.e. in both 
unstimulated and stimulated cells; ANOVA interaction 
term not significant) (Fig.  2c). CD46 pathway markers 
were studied before and after stimulation by determin-
ing the levels of mRNA for CD46 molecule and its two 
isoforms, Cyt-1 and Cyt-2. In both untreated patients and 
Ctrl, the anti-CD3/CD46 MoAb stimulation induced the 
expression of CD46 mRNA (Fig. 2d), but this effect was 
unrelated to therapy (ANOVA interaction between “time 
and stimulation” not significant and “time effect” not sig-
nificant). However, the levels of mRNA for Cyt-1 isoform 
decreased after anti-CD3/CD46 MoAb stimulation in 
patients untreated (at T0) and treated (at T12 and T24) 
and in Ctrl (Fig.  3a). On the contrary, the stimulation 
had no modulation effect on Cyt-2 mRNA, which levels 
were significantly higher than those of Cyt-1 (p < 0.001 
at all time points) in patients and in Ctrl (Fig.  3b). This 
pattern was confirmed by the high and significant cor-
relation, present at all time points and stimulation con-
ditions, between Cyt-1 and Cyt-2 levels (Additional 
file 5: Figure S3). The ratio of Cyt-2 to Cyt-1 mRNA lev-
els increased after stimulation in both patients and Ctrl 
(Fig. 3c), and this is in line with previous results indicat-
ing that the two isoforms have opposite effects (Cyt-1, 
immunosuppressive, and Cyt-2, immunostimulating) 
[12]. The relative reduction of Cyt-1 mRNA in stimu-
lated cells (denominator) with a stable Cyt-2 mRNA 
(numerator) determined the increased ratio. The mean 
ratio was significantly reduced at 12  months of IFN-β 
treatment both in stimulated and unstimulated  CD4+ 
cells (ANOVA interaction not significant) suggesting 
that IFN-β may alter the relative expression of the two 
isoforms in favour of Cyt-1 (relative decrease in Cyt-2, 
numerator, and/or increase in Cyt-1, denominator). 
Unstimulated  CD4+ cells from patients, at all three 
time points, and from Ctrl contained very low levels of 
IL-10 mRNA (Fig. 3d). This cytokine can be produced by 
Tr1 and is considered important for modulating T-cell 
response. After in vitro induction of Tr1-like cells, IL-10 
levels increased in all groups of samples tested. However, 
IL-10 mRNA significantly diminished at T24 compared 
with T0 in stimulated cells obtained from IFN-β-treated 
patients (interaction significant). Then, we investigated, 
by a multivariable regression, to which extent CD18, 
CD49b, CD46, Cyt-1, and Cyt-2 biomarkers contributed 
to regulating IL-10 mRNA levels. This analysis predicted 
that IL-10 mRNA levels increased with CD49b levels 
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in both stimulated and unstimulated cells and, surpris-
ingly, with Cyt-2 mRNA expression, but only in stimu-
lated cells (Table  1). In more detail, for every doubling 
of CD49b levels, the model predicted a 39% increase in 
IL-10 mRNA in unstimulated and a 110% increase in 
stimulated cells, whereas for a doubling in Cyt-2 levels, 
the model predicted a 47% increase in stimulated cells. 
By contrast, the effect of Cyt-1 change on IL-10 mRNA 
levels was opposite because every doubling of Cyt-1 
expression determined an 84% decrease in IL-10 mRNA 
in stimulated cells.
Association between Treg levels and disease activity
Due to profound inter-individual variations in the mod-
ulation of TregCM, TregEM,  CD120b+ nTreg, and Tr1 
subsets, patients were divided into three groups based on 
the variations of each Treg subset (increase, maintenance 
or a slight increase, or decrease) at 24 months of therapy. 
We found no evidences of EDSS changes (at most a half 
point change) in the different groups (Additional file  6: 
Figure S4).
Patients were also divided into two groups based on the 
presence of clinical relapses or a stable course of the dis-
ease (Table 2).
Compared with stable patients, those experiencing 
relapses were younger, had a higher percentage of naïve 
Table 1 Multivariable regression analysis of predicting factors affecting IL-10 mRNA levels
*Calculated by exponentiating the coefficients reported in “effect on  log2 IL-10 column”
**Representing the % of change in IL-10 mRNA levels per each hypothetical doubling of the respective predictor level
Effect on  log2 IL‑10 95% confidence interval p* Effect on IL‑10 % of change** 95% 
confidence 
interval
log2 CD49b in:
 Unstimulated 0.476 0.157: 0.796 0.003 1.39 + 39 1.115: 1.736
 Stimulated 1.068 0.769: 1.367 0.000 2.1 + 110 1.704: 2.580
log2 Cyt-1 in:
 Unstimulated − 0.097 − 0.795: 0.601 0.785 0.93 − 7 0.576: 1.517
 Stimulated − 1.961 − 2.562: − 1.360 0.000 0.26 − 84 0.169: 0.390
log2 Cyt-2 in:
 Unstimulated 0.067 − 0.432: 0.565 0.793 1.05 + 5 0.741: 1.479
 Stimulated 0.558 0.121: 0.995 0.012 1.47 + 47 1.088: 1.992
Stimulated vs unstimulated at:
 T0 2.275 1.457: 3.093 0.000 4.84 + 384 2.746: 8.534
 T12 2.107 1.254: 2.960 0.000 4.31 + 331 2.384: 7.782
 T24 1.822 0.976: 2.667 0.000 3.53 + 253 1.967: 6.352
Table 2 Baseline characteristics of patients who experienced or not clinical relapses during the study course
SD standard deviation, Treg regulatory T cells, TregCM Treg central memory, TregEM Treg effector memory
p-value calculation was done using Chi squared (χ2) or two independent sample t-test for categorical or continuous variables, respectively
* Data determined at the pre-therapy time point
** These data are available for a subgroup of patients only
Relapse yes (n = 31) Relapse no (n = 117) Significance
Gender (♀); patients (%) 20 (64.51) 72 (61.53) χ2 = 0.92, p = 0.761
Age (years); mean (SD) 30.45 (± 7.66) 38.02 (± 10.42) t = − 3.77, p < 0.001
EDSS*; mean (SD) 1.32 (± 0.83) 1.55 (± 0.86) t = − 1.34, p = 0.181
Enhancing lesions**; patients (%) 18/31 (58) 55/81 (67.9) χ2 = 1.36, p = 0.243
Naïve Treg percentage*; mean (SD) 33 (± 14) 28.16 (± 11.09) t = 2.03, p = 0.044
TregCM percentage*; mean (SD) 42.63 (± 13.12) 46.52 (± 8.17) t = − 2.04, p = 0.043
TregEM percentage*; mean (SD) 23.39 (± 6.28) 25.06 (± 8.10) t = 0.27, p = 0.290
Tr1 percentage*; mean (SD) 3.83 (± 1.22) 4.68 (± 2.13) t =− 2.10, p = 0.037
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Treg and a lower percentage of TregCM and Tr1 at pre-
therapy time point. A mixed ANOVA on the percent-
ages of each Treg subsets, performed with relapses (two 
levels: yes/no) and time (5 levels: T0, T6, T12, T18, and 
T24 time points) as independent variables, and age at 
pre-therapy as covariate, revealed no differences in Treg 
subset percentages in patients with or without experience 
of clinical relapses. As the main effect of IFN-β on Treg 
values was most evident in the first months of treatment, 
analyses were repeated considering only T0, T6, and T12 
time points and comparing patients who had relapses in 
the first year of therapy vs those without relapses, but the 
results did not change. However, since this last analy-
sis highlighted a trend toward significance for TregCM 
(group x time interaction (F[2200] = 1.49, p = 0.08), a 
Newman Keuls post hoc test was performed, revealing 
an increment over time of TregCM percentage (T0 vs 
T12 and T6 vs T12: p = 0.001) in the group with stable 
disease.
Patients were also divided into two groups depend-
ing on whether they manifested or not new lesions in 
T2 or new enhancing lesions at MRI (Additional file  7: 
Table S3). This analysis was performed only in patients in 
whom MRI and experimental data of all Treg subsets, at 
all time points, were available. Compared with radiologi-
cally stable patients, those with new lesions in T2 were 
younger and had more enhancing lesions at pre-therapy. 
Then, a mixed ANOVA on each Treg subsets was per-
formed using new lesions (two levels: yes/no) and time (5 
levels: T0, T6, T12, T18, and T24 time points) as inde-
pendent variables, and age at pre-therapy as a covari-
ate. The critical interaction “new lesions x time” was not 
significant, indicating that the longitudinal changes of 
Treg subsets never differed between the two groups. This 
result remained unchanged in patients experiencing new 
lesions in the first year of therapy compared with those 
without new lesions. However, the mixed ANOVAs on 
the percentage of Tr1 demonstrated a statistically signifi-
cant critical interaction “group x time” (F[4228] = 2.51, 
p = 0.04) and Newman Keuls post hoc test highlighted 
that, in the group of patients stable at MRI, Tr1 values 
grew at every time points. In patients with reactivation at 
MRI there was no Tr1 increase.
Discussion
The analysis of Treg subsets performed in naïve and 
IFN-β-treated patients led to conflicting results [9–14, 
19], possibly due to differences in study design, type of 
enrolled patients, sample size, timing of treatment, time 
between disease onset and treatment inception, duration 
of follow-up, type and dosage of IFN-β, and approaches 
used for identifying and analyzing Treg. The current 
study, that overcomes some of the limitations of the 
previous works, demonstrated that specific Treg sub-
sets gradually increased at 6 months of IFN-β treatment 
and continued to augment during the whole treatment 
period. This result is in congruence with previous studies 
reporting that the suppressive function and frequency of 
peripheral nTreg have been improved in the first months 
of therapy [9–11]. However, we also observed that IFN-β 
therapy induced an increased percentage of memory 
Treg subsets, although the observed expansion under-
took at different time points for each subset. TregCM 
firstly expanded (between T6 and T12), while TregEM 
only increased later (between T18 and T24). Of note, 
TregCM were the most effective nTreg cells, due to the 
expression of CCR7. The expansion of memory Treg was 
counterbalanced by a reduction of naïve Treg. The per-
centage of Tr1 cells significantly increased from T6 and 
T12 and remained high for the entire observation period. 
Despite the profound, significant decrease of the number 
of lymphocytes, a well-known effect of IFN-β therapy 
[23], also the absolute number of Tr1 increased during 
the therapy.
These findings suggest that IFN-β induces coordinated 
actions in different Treg subsets by both inhibitory and 
stimulatory feedbacks leading to a balanced response 
that fulfils its protective function while preventing 
immunopathology.
As reported for several other immune cells [24], we also 
found that Treg subsets from patients vary widely before 
and after therapy, which may indicate the use of adaptive 
strategies, compensatory pathways and functional redun-
dancy to maintain their functions.
The comparison of patients according to presence or 
absence of relapses revealed that clinically stable patients 
displayed an increase in TregCM and a decrease in naïve 
Treg over time. This data is consistent with higher sup-
pressive activity of TregCM subset and low suppressive 
action of naïve Treg [25]. In addition, Tr1 constantly 
increased only in patients with stable MRI while in those 
with new lesions the percentage of Tr1 increased in the 
first year of therapy, but then decreased.
A modulation of Tr1 was observed in in  vitro experi-
ments. Indeed, treated patients showed higher CD49b 
mRNA expression suggesting that this molecule might 
function as a marker associated with the therapeutic 
effects of IFN-β. Conversely, CD18 mRNA was not asso-
ciated with the outcome of IFN-β therapy. Accordingly, 
CD18 is known to be a less specific marker since it is 
expressed by many cell types [26].
We also assessed the involvement of the CD46 path-
way in determining the induction of the Tr1-like phe-
notype in  CD4+ cells from patients. Despite the ex vivo 
 CD18+CD49b+ Tr1 percentage increase, the suppres-
sive function of Tr1 appeared to be defective in patients 
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since the levels of IL-10 mRNA, produced after in vitro 
stimulation by Tr1-like cells, were lower than those 
observed in healthy subjects. In addition, IL-10 mRNA 
expression further decreased in patients treated for 
24  months with IFN-β. These results are aligned with 
those reporting that, under similar in  vitro conditions, 
cells from IFN-β-treated and untreated patients secreted 
less IL-10 (measured by an ELISA assay) than cells from 
Ctrl [27]. In addition, anti-CD3/CD46-stimulated  CD4+ 
cells of patients exhibited a defective response to IL-10 
stimulation not reverted by IFN-β treatment [13]. There-
fore, our in vitro results indicate that, in patients, CD3/
CD46-induced Tr1-like cells are only partially function-
ing and IFN-β might not be fully capable of restoring 
this impairment. Furthermore, these data also suggest 
that  CD18+CD49b+ Tr1 cells identified ex  vivo after 
IFN-β treatment may be different from the Tr1-like cells 
induced by anti-CD3/CD46 MoAb stimulation and may 
exert different activities Indeed, it has been proposed that 
Treg adopt several different mechanisms for the down 
modulation of immune responses. One of these mecha-
nisms, the ectoenzymatic activity, can be particularly rel-
evant in CNS autoimmunity [28]. In addition, Treg may 
also show other functions, not limited to immune sup-
pression. For instance, these cells are able to promote 
oligodendrocyte differentiation and remyelination in a 
mouse model of lysolecithin-induced focal demyelina-
tion. This occurs through the release of CCN3, a growth-
regulatory protein usually expressed in the developing 
brain [29].
Dropouts were high in this study, but this does not 
weaken the conclusions because the modulations of Treg 
subsets we have observed at 24  months from therapy 
beginning were already found at 12  months of therapy, 
when the dropout was lower. Dropouts rates are known 
to differ widely according to study duration and study 
type (randomized controlled trial or observational). 
However, a 38% dropout in IFN-β 1a-treated patients, at a 
median of 421 days of therapy [30], and a dropout in 37% 
at median time of 1.7  years in a recent real-life clinical 
study [31], have been recently reported. Finally, patients 
treated with subcutaneous IFN-β-1a have a probability of 
persistence on therapy at 3 years of 43.6% [32]. These val-
ues are similar to that we have found in this study.
The biological basis of altered T-cell response in 
patients after anti-CD3/CD46 MoAb stimulation was 
also elucidated by quantifying the levels of mRNA for 
Cyt-1 and Cyt-2 isoforms. In a CD46 transgenic mouse 
model, Cyt-1 and Cyt-2 isoforms proved to play antago-
nistic roles in inflammation [12, 33], with Cyt-1 pro-
moting the suppression of the inflammatory reaction 
and Cyt-2 inducing overall increase in inflammation by 
interfering with IL-10 production [12]. As previously 
described [27], we demonstrated a higher level of expres-
sion of Cyt-2 compared to Cyt-1, regardless of in  vitro 
stimulation, with no significant differences between 
patients and Ctrl and no change after IFN-β treatment. 
However, differently to the report that described a sig-
nificant increase in the CD46-induced Cyt-2 isoform, 
with no changes in Cyt-1 in patients, either treated or 
untreated with IFN-β [27], we found a decrease of Cyt-1 
mRNA, due to anti-CD3/CD46 MoAb stimulation. Of 
note, our work overcomes the limitations of the previous 
one, which included reduced number of patients, differ-
ent numbers of treated and untreated patients, and only 
one-time point for data collection. Considering that the 
expression of these two subunits may change during dif-
ferent stages of T-cell activation [12], and that they may 
be reciprocally regulated, we also calculated the ratio of 
Cyt-2-to-Cyt-1 mRNA expression. We found a slight, yet 
significant, decrease in Cyt-2-to-Cyt-1 ratio after IFN-β 
treatment compared to pre-treatment values, although 
the same ratio increased at all time points upon anti-
CD3/CD46 MoAb stimulation both in patients and Ctrl 
when compared to the unstimulated counterpart. To 
better evaluate the reciprocal role of Cyt-1 and Cyt-2 in 
influencing IL-10 mRNA levels and elucidate the reasons 
for the minor induction of IL-10 we fitted a multivari-
able regression. This analysis reported a strong positive 
association between the expression of the Tr1-associated 
gene CD49b and IL-10 but, at the same time, unexpect-
edly, a positive association between IL-10 and Cyt-2 
mRNA levels and a negative association between IL-10 
and Cyt-1 mRNA levels. Once again, this finding may 
represent another facet of the disrupted IL-10 pathway in 
MS which is uncorrected by IFN-β treatment.
Conclusion
IFN-β induces the expansion of nTreg subsets endowed 
with a high suppressive activity, especially in clinically 
stable patients (without relapses and new MRI lesions); 
this may represent one of the mechanisms by which 
the IFN-β exerts its effects. IFN-β also induced a strong 
expansion of Tr1 but, surprisingly, in vitro expansion of 
Tr1-like cells yielded a low production of IL-10, which is 
the typical Tr1 suppressive cytokine.
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Additional file 1: Table S1. Number of patients included in the study 
and dropouts occurring at each time points. The therapy time points 
were: T0, before therapy initiation; T6, T12, T18 and T24, after 6, 12, 18, and 
24 months of IFN-β, respectively. 
Additional file 2: Table S2. Number of samples received at T12 and 
T24 for MxA quantification and patient subdivision according to MxA 
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induction. The MxA quantification was performed before IFN-β therapy 
initiation (T0) and then after 12 (T12) and 24 (T24) months of therapy. 
Additional file 3: Figure S1. The gating strategy ensures the quality and 
continuity of data acquired for the whole blood and allows the identifica-
tion of: (A) single-cell lymphocytes, which can be distinguished by their 
forward scatter/side scatter properties;(B) after lymphocyte gating, dou-
blets are excluded, followed by exclusion of dead or autofluorescent cells; 
(C) naive, central memory (CM), and effector memory (EM)  CD4+ cells 
based on the expression of C45RA and CCR7 markers; (D)  CD4+ Tr1 cells 
based on the expression of CD18 and high level of CD49b expression; (E) 
 CD4+ Treg cells based on positive expression of CD25 and low/negative 
expression of CD127; and (F) Treg subsets population (naïve Treg, TregCM, 
and TregEM) based on the expression of C45RA and CCR7 markers. (G and 
H) CD120b (TNFR2) expressing cells (black line) within nTreg population 
(dark grey) compared to naïve  CD4+ lymphocytes (grey) and monocytes 
(light grey), which are respectively negative and positive for the expres-
sion of CD120b antigen. 
Additional file 4: Figure S2. The absolute number of total lymphocytes 
(A), naïve Treg (B), TregCM (C), TregEM (D),  CD120b+ nTreg (E), and Tr1 (F) 
after IFN-β treatment was investigated at T0: before therapy initiation and 
T6, T12, T18, and T24: after 6, 12, 18, and 24 months of IFN-β, respectively. 
Estimated means are shown, connected by continuous lines, along with 
error bars representing the 95% confidence interval. Black lines indicate 
statistically significant decreases, while red lines indicate statistically 
significant increases. 
Additional file 5: Figure S3. Correlation between Cyt-1 and Cyt-2 mRNA 
expression after stimulation. Scatterplot representing the correlations 
between Cyt-1 and Cyt-2 values at the indicated time points and condi-
tions. Black lines were obtained by linear regression. 
Additional file 6: Figure S4. Subdivision of patients according to the 
variations of each Treg subset at T24. Patients were grouped based on the 
increase (↑), maintenance or slight increase (=/↑), or decrease (↓) of the 
different Treg subset percentages after 24 months of IFN-β therapy. There-
fore, only 86 patients that completed the follow-up were included in the 
analysis. TregCM ↑: ≥ 6%, =/↑: -1 to < 6%, ↓: < -1%; TregEM ↑: ≥ 5%, =/↑: 
-1 to < 5%, ↓: < -1%;  CD120b+ nTreg ↑: ≥ 10%, =/↑: 0 to < 10%, ↓: < 0%; 
Tr1↑: ≥ 4.5%, =/↑: 0 to < 4.5%, ↓: < 0%. In red: median EDSS value. 
Additional file 7: Table S3. Association with disease activity. Patients 
were divided in two groups depending on whether they manifested or 
not new lesions in T2 or new enhancing lesions.
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